Gmail Calendar Documents Reader Web more »
Recently Visited Groups | Help | Sign in
Google Groups Home
Cathelicidin-derived peptide for the control of sinusitis
There are currently too many topics in this group that display first. To make this topic appear first, remove this option from another topic.
There was an error processing your request. Please try again.
flag
  1 message - Collapse all  -  Translate all to Translated (View all originals)
The group you are posting to is a Usenet group. Messages posted to this group will make your email address visible to anyone on the Internet.
Your reply message has not been sent.
Your post was successful
 
From:
To:
Cc:
Followup To:
Add Cc | Add Followup-to | Edit Subject
Subject:
Validation:
For verification purposes please type the characters you see in the picture below or the numbers you hear by clicking the accessibility icon. Listen and type the numbers you hear
 
Kofi  
View profile  
(1 user)  More options May 14, 6:33 pm
Newsgroups: alt.baldspot, sci.life-extension, alt.support.sinusitis
From: Kofi <k...@anon.un>
Date: Thu, 14 May 2009 02:33:05 -0600
Local: Thurs, May 14 2009 6:33 pm
Subject: Cathelicidin-derived peptide for the control of sinusitis
Am J Rhinol Allergy. 2009 Jan-Feb;23(1):46-51.

Effects of an LL-37-derived antimicrobial peptide in an animal model of
biofilm Pseudomonas sinusitis.
Chennupati SK, Chiu AG, Tamashiro E, Banks CA, Cohen MB, Bleier BS,
Kofonow JM, Tam E, Cohen NA.
Department of Otorhinolaryngology-Head and Neck Surgery, University of
Pennsylvania, Philadelphia, Pennsylvania, USA.

BACKGROUND: LL-37, an innate immunity protein expressed within sinonasal
mucosa, has in vitro antibacterial and antifungal properties as well as
efficacy against preformed Pseudomonas aeruginosa biofilms. We
hypothesize that a 24 amino acid peptide derivative of LL-37 will show
efficacy against biofilm-forming P. aeruginosa in an established animal
model of sinusitis. METHODS: Five groups of six New Zealand rabbits were
each infected with P. aeruginosa (PAO-1) and fitted with irrigating
catheters 7 days later. Each group was instilled with either one of
three different concentrations of peptide, a positive control of topical
tobramycin, or the carrier solution without the peptide once a day for
10 days. Nasal diluent was collected throughout the irrigation period to
assess for persistence or resolution of infection by determining
colony-forming units (CFU). At study end, sinus mucosa was harvested for
histological assessment of inflammation and SEM evaluation for ciliary
integrity and presence of biofilms. RESULTS: Topical tobramycin at 400x
minimum inhibitory concentration and 2.5 mg/mL of peptide were effective
in significantly lowering CFUs after 10 days of irrigation. Histological
evaluation showed increased signs of inflammation in a dose-dependent
manner within mucosa and bone of the groups receiving the peptide. SEM
analysis showed ciliary loss in a dose-dependent manner. Biofilms were
present in all groups except for the highest concentration of peptide
and tobramycin. CONCLUSION: High concentrations of LL-37-derived peptide
showed in vivo ability to eradicate Pseudomonas biofilms and decrease
bacterial counts. However, increasing concentrations of peptide showed
proinflammatory and ciliotoxic effects on sinus mucosa.

Publication Types:
*  Research Support, Non-U.S. Gov't

PMID: 19379612


    Reply to author    Forward  
You must Sign in before you can post messages.
To post a message you must first join this group.
Please update your nickname on the subscription settings page before posting.
You do not have the permission required to post.
End of messages
« Back to Discussions « Newer topic     Older topic »

Create a group - Google Groups - Google Home - Terms of Service - Privacy Policy
©2009 Google